Compare Amgen, Inc. (AMGN) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs MasTec Inc — how do they compare? Amgen, Inc. trades at $358.74 (market cap $196.12B), while MasTec Inc trades at $363.74 (market cap $29.47B). The key difference: Amgen, Inc. is far larger — about 6.7× MasTec Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| AMGN | MTZ | |
|---|---|---|
Market Cap | $196.12B | $29.47B |
Sector | Health | Technology |
52-Week High | $388.16 | $437.51 |
52-Week Low | $271.18 | $170.24 |
Enterprise Value | $241.41B | $32.21B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MasTec (MTZ) trades at $372.89, down 3.07% on the day, with a neutral technical signal and strong fundamental backdrop. The stock shows robust earnings momentum, beating estimates for three consecutive quarters, and benefits from a record $20.3 billion backlog. Recent acquisition of The Superior Group for $1.65 billion enhances its data center infrastructure capabilities, positioning the company for growth in AI-driven power demand and broadband expansion.
Outlook remains positive with 88.9% analyst buy ratings and a $479.85 consensus price target implying 28.7% upside. Key risks include execution of large acquisitions and integration challenges, while high P/E of 65.3 suggests premium valuation. Revenue growth and margin expansion from infrastructure spending trends support long-term potential, but investors should monitor debt levels and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
